The monoclonal antibody trastuzumab is a receptor blocker that has been proven to be clinically very effective in HER-2/neu-overexpressing tumors.
O anticorpo monoclonal trastuzumab é un bloqueador de receptor que probou ser clinicamente moi efectivo en tumores con sobreexpresión de HER-2/neu.